David T Dunn

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. ncbi request reprint HIV drug resistance testing: is the evidence really there?
    David T Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 9:641-8. 2004
  2. doi request reprint Genotypic resistance testing in routine clinical care
    David T Dunn
    MRC Clinical Trials Unit, London, UK
    Curr Opin HIV AIDS 6:251-7. 2011
  3. ncbi request reprint A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators
    D T Dunn
    HIV Division, Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Acquir Immune Defic Syndr 38:553-9. 2005
  4. pmc Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring
    D T Dunn
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, United Kingdom
    Antimicrob Agents Chemother 55:4575-80. 2011
  5. ncbi request reprint Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis
    David Dunn
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 362:1605-11. 2003
  6. doi request reprint Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults
    David Dunn
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Infect Dis 197:398-404. 2008
  7. ncbi request reprint The dangers of inferring treatment effects from observational data: a case study in HIV infection
    David Dunn
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Control Clin Trials 23:106-10. 2002
  8. ncbi request reprint Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
    Diana M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 7:293-303. 2002
  9. ncbi request reprint Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection
    Diana M Gibb
    Medical Research Council Trials Unit, London, UK
    Pediatr Infect Dis J 23:446-50. 2004
  10. ncbi request reprint A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial
    Hannah Green
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 11:857-67. 2006

Detail Information

Publications30

  1. ncbi request reprint HIV drug resistance testing: is the evidence really there?
    David T Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 9:641-8. 2004
    ..To assess the strength of evidence supporting the routine use of HIV drug resistance testing...
  2. doi request reprint Genotypic resistance testing in routine clinical care
    David T Dunn
    MRC Clinical Trials Unit, London, UK
    Curr Opin HIV AIDS 6:251-7. 2011
    ..Genotypic resistance testing has become part of routine clinical management of HIV-infected patients. Focussing on observational studies, this review looks at recent advances in this area...
  3. ncbi request reprint A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators
    D T Dunn
    HIV Division, Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Acquir Immune Defic Syndr 38:553-9. 2005
    ..To assess the clinical utility of phenotypic resistance testing in addition to genotypic resistance testing among HIV-1-infected patients experiencing virologic failure and with limited therapeutic options...
  4. pmc Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring
    D T Dunn
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, United Kingdom
    Antimicrob Agents Chemother 55:4575-80. 2011
    ..This information should be considered in future treatment guidelines relevant to resource-poor settings...
  5. ncbi request reprint Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis
    David Dunn
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 362:1605-11. 2003
    ..We estimated 12-month risks of progression to AIDS and death, by age and most recent measurement of CD4 T-cell percentage (CD4%) or viral load, in children receiving no antiretroviral therapy or zidovudine monotherapy only...
  6. doi request reprint Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults
    David Dunn
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Infect Dis 197:398-404. 2008
    ..Currently, there are no comparable estimates of the short-term risk of disease progression in the absence of effective antiretroviral therapy for human immunodeficiency virus (HIV)-infected adults and children...
  7. ncbi request reprint The dangers of inferring treatment effects from observational data: a case study in HIV infection
    David Dunn
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Control Clin Trials 23:106-10. 2002
    ..Examples such as this emphasize the need to regard randomized controlled trials as the primary mechanism for assessing therapeutic efficacy...
  8. ncbi request reprint Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
    Diana M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 7:293-303. 2002
    ....
  9. ncbi request reprint Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection
    Diana M Gibb
    Medical Research Council Trials Unit, London, UK
    Pediatr Infect Dis J 23:446-50. 2004
    ..There are few data on the decline of CD4 cells or percentage during unplanned treatment interruptions in HIV-infected children...
  10. ncbi request reprint A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial
    Hannah Green
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 11:857-67. 2006
    ..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure...
  11. doi request reprint The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom
    Hannah Green
    HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
    J Acquir Immune Defic Syndr 49:196-204. 2008
    ..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable...
  12. doi request reprint Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA)
    Charles F Gilks
    Imperial College, London, UK
    Antivir Ther 17:1363-73. 2012
    ..Boosted protease inhibitor (bPI) monotherapy (bPImono) potentially has substantial cost, safety and operational benefits. It has never been evaluated as second-line antiretroviral therapy (ART) in Africa...
  13. ncbi request reprint Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy
    Alexander J Frater
    Jefferiss Trust Laboratories, Wright Fleming Institute, Imperial College School of Medicine, St Mary s Campus, London, UK
    AIDS 16:1139-46. 2002
    ..Our objective was to compare the response, in our clinic, of African HIV-1-infected patients with their British and European contemporaries treated with the same regimes...
  14. ncbi request reprint Interval-censored survival time data: confidence intervals for the non-parametric survivor function
    Ruth L Goodall
    MRC Clinical Trials Unit, London, UK
    Stat Med 23:1131-45. 2004
    ..In a simulation study the likelihood ratio method gave the most accurate confidence intervals with coverage consistently close to the nominal level of 95 per cent...
  15. pmc Persistence of HIV-1 transmitted drug resistance mutations
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Infect Dis 208:1459-63. 2013
    ..Our estimates are important for informing HIV transmission models. ..
  16. pmc Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial
    Nicholas I Paton
    MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, United Kingdom
    JAMA 308:353-61. 2012
    ..Therapies to decrease immune activation might be of benefit in slowing HIV disease progression...
  17. doi request reprint HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
    Daniella N Chilton
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 15:985-91. 2010
    ..We examined the characteristics of HIV-1 drug resistance in antiretroviral treatment (ART)-naive individuals migrating to the UK...
  18. pmc Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, UK
    BMC Med Res Methodol 12:30. 2012
    ..However estimates of the prevalence of TDR will also be distorted if some ART-experienced patients are misclassified as ART-naïve...
  19. pmc Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland
    D M Gibb
    Medical Research Council Clinical Trials Unit, London NW1 2DA
    BMJ 327:1019. 2003
    ..To describe changes in demographic factors, disease progression, hospital admissions, and use of antiretroviral therapy in children with HIV...
  20. ncbi request reprint Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission
    D M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Lancet 356:904-7. 2000
    ..We examined the effect of risk factors, including mode of delivery, on the vertical transmission rate...
  21. ncbi request reprint Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy
    Marietta Charakida
    Vascular Physiology Unit, Institute of Child Health, London, UK
    Circulation 112:103-9. 2005
    ..The purpose of this study was to determine the impact of HIV infection and antiretroviral therapy (ART) on markers of early vascular disease in children...
  22. doi request reprint Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children
    K Boyd
    Medical Research Council Clinical Trials Unit, London, UK
    AIDS 24:1213-7. 2010
    ..This leads to clinical dilemma when one marker is below the threshold, whereas the other is above...
  23. ncbi request reprint Maternal viral load, CD4 cell count and vertical transmission of HIV-1
    S O'Shea
    Department of Virology, United Medical School, Guy s Hospital, London, United Kingdom
    J Med Virol 54:113-7. 1998
    ..High viral load is also associated with premature delivery. Maternal viral load is therefore a useful marker on which to base management decisions during pregnancy...
  24. ncbi request reprint Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection
    D T Dunn
    Medical Research Council Clinical Trials Unit, Institute of Child Health, London, UK
    Pediatr Infect Dis J 20:715-6. 2001
    ..These estimates may assist clinicians in assessing the likelihood of infection in an individual child and in using the currently available assays cost effectively...
  25. pmc Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study
    David I Dolling
    Medical Research Council Clinical Trials Unit, London, UK
    J Antimicrob Chemother 68:2339-43. 2013
    ..To determine protease mutations that develop at viral failure for protease inhibitor (PI)-naive patients on a regimen containing the PI atazanavir...
  26. pmc Transmission network parameters estimated from HIV sequences for a nationwide epidemic
    Andrew J Leigh Brown
    Institute of Evolutionary Biology, University of Edinburgh, London, United Kingdom
    J Infect Dis 204:1463-9. 2011
    ..Recent developments in molecular phylodynamics have provided new routes to obtain these parameter estimates, and current clinical practice provides suitable data for entire infected populations...
  27. doi request reprint Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data
    L Harrison
    HIV Group and Hub for Trials Methodology Research, MRC Clinical Trials Unit and University College London, 222 Euston Road, London, NW1 2DA, U K
    Stat Med 28:3260-75. 2009
    ..Our approach is compared with other methods and illustrated through a simulation study and an analysis of the association between HIV-1 subtype and immunological response after starting antiretroviral therapy...
  28. doi request reprint What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?
    D Grover
    Centre of Sexual Health and HIV Research, Department of Primary Care and Population Sciences, Mortimer Market Centre, London, UK
    J Antimicrob Chemother 61:705-13. 2008
    ..Changing antiretroviral therapy following emergence of MDR HIV-1 may be associated with improved short-term virological response...
  29. ncbi request reprint A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy
    H Green
    Medical Research Council Clinical Trials Unit, London, UK
    HIV Med 5:278-83. 2004
    ..To assess the medium-term safety of discontinuing prophylaxis (primary or secondary) for opportunistic infections following an effective response to antiretroviral therapy...
  30. doi request reprint Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK
    P J Easterbrook
    Department of HIV GU Medicine, Kings College London School of Medicine at Guy s, London, UK
    HIV Med 9:47-56. 2008
    ..We describe the patterns of antiretroviral drug use at treatment initiation from 1996 to 2005 in a large UK multicentre cohort...